Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant

McMaster University

$60,000.00

EPITEC - Epidemiology of ThromboEmbolism in Critical care

FY 2009-10

Summary
Blood clots that develop in veins of the legs or arms because of serious illness and inactivity may break off and travel to arteries in the lungs. Lung clots are extremely dangerous and are a leading cause of hospital death worldwide. The most seriously ill hospitalized patients on life support in the intensive care unit are at particularly high risk of developing clots. Early small studies suggested that blood clots increase dependence on life support and time in hospital, decreasing the chance of survival. In the Epidemiology of Thromboembolism In Critical care Study EPITEC, we will carefully examine two key problems occurring in medical and surgical patients: risk factors for these clots, and consequences of these clots. Risk factors for clot development may relate to new or established conditions which can not be changed, or may relate to interventions used in the ICU which can be modified. Knowledge about risk factors that can be modified will help to identify patients who require increased attention and possibly additional measures to prevent, diagnose and treat clots. Knowing about these risk factors will also point out ways to change practice, so the overall chance of developing blood clots can be reduced. EPITEC will also carefully analyze the true impact of blood clots in the largest group of critically ill patients ever investigated, by considering the effect of many new and chronic conditions and recent procedures. This study will be done by Canadas leading critical care research group (the Canadian Critical Care Trials Group), alongside a large high quality ongoing international trial on blood clot prevention, which allows us to take advantage of some existing information, personnel and resources. Doing EPITEC this way means quicker, more cost-effective creation of important new knowledge about this potentially life-threatening problem. Ultimately, EPITEC will tell us why these blood clots occur and how they can best be prevented, diagnosed and treated
Program
Operating Grant
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
201264
Name
Cook Deborah J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Public, Community & Population Health 2
Projecttitle
EPITEC - Epidemiology of ThromboEmbolism in Critical care
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Critical Illness; Epidemiology; Intensive Care Unit (Icu); Thrombosis
Abstract
Blood clots that develop in veins of the legs or arms because of serious illness and inactivity may break off and travel to arteries in the lungs. Lung clots are extremely dangerous and are a leading cause of hospital death worldwide. The most seriously ill hospitalized patients on life support in the intensive care unit are at particularly high risk of developing clots. Early small studies suggested that blood clots increase dependence on life support and time in hospital, decreasing the chance of survival. In the Epidemiology of Thromboembolism In Critical care Study EPITEC, we will carefully examine two key problems occurring in medical and surgical patients: risk factors for these clots, and consequences of these clots. Risk factors for clot development may relate to new or established conditions which can not be changed, or may relate to interventions used in the ICU which can be modified. Knowledge about risk factors that can be modified will help to identify patients who require increased attention and possibly additional measures to prevent, diagnose and treat clots. Knowing about these risk factors will also point out ways to change practice, so the overall chance of developing blood clots can be reduced. EPITEC will also carefully analyze the true impact of blood clots in the largest group of critically ill patients ever investigated, by considering the effect of many new and chronic conditions and recent procedures. This study will be done by Canadas leading critical care research group (the Canadian Critical Care Trials Group), alongside a large high quality ongoing international trial on blood clot prevention, which allows us to take advantage of some existing information, personnel and resources. Doing EPITEC this way means quicker, more cost-effective creation of important new knowledge about this potentially life-threatening problem. Ultimately, EPITEC will tell us why these blood clots occur and how they can best be prevented, diagnosed and treated
Competitiondate
201003
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cook, Deborah J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $60,000~ $0~